NCT01839630View on ClinicalTrials.gov

Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China

CompletedOBSERVATIONAL
Enrollment

302

Participants

Timeline

Start Date

May 30, 2013

Primary Completion Date

August 6, 2016

Study Completion Date

December 29, 2016

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006)

sorafenib treatment (including dose, duration, modification) and TACE procedure are decided by the investigator

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY